Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to -$4.2 million.

  • Lisata Therapeutics' Net Income towards Common Stockholders rose 1381.34% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.2 million, marking a year-over-year increase of 1204.44%. This contributed to the annual value of -$20.0 million for FY2024, which is 410.27% up from last year.
  • According to the latest figures from Q3 2025, Lisata Therapeutics' Net Income towards Common Stockholders is -$4.2 million, which was up 1381.34% from -$4.7 million recorded in Q2 2025.
  • Lisata Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$4.0 million during Q2 2023, with a 5-year trough of -$6.2 million in Q1 2023.
  • For the 3-year period, Lisata Therapeutics' Net Income towards Common Stockholders averaged around -$5.0 million, with its median value being -$4.9 million (2024).
  • Data for Lisata Therapeutics' Net Income towards Common Stockholders shows a peak YoY increase of 1407.27% (in 2024) and a maximum YoY decrease of 2525.45% (in 2024) over the last 5 years.
  • Lisata Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$5.4 million in 2023, then increased by 14.07% to -$4.6 million in 2024, then grew by 7.83% to -$4.2 million in 2025.
  • Its Net Income towards Common Stockholders was -$4.2 million in Q3 2025, compared to -$4.7 million in Q2 2025 and -$4.7 million in Q1 2025.